Crossmark

Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab

Crossref DOI link: https://doi.org/10.1007/s10096-019-03588-x

Published Online: 2019-05-22

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Paes, Bosco https://orcid.org/0000-0002-3308-2706
Saleem, Mahwesh

Kim, Doyoung

Lanctôt, Krista L.

Mitchell, Ian
Funding

Funding for this research was provided by:

AbbVie (A05-130)
License Information

Text and Data Mining valid from 2019-05-22
More Information

Article History

Received: 8 April 2019

Accepted: 13 May 2019

First Online: 22 May 2019

Compliance with ethical standards

:

: B.P. I.M. and K.L. have received investigator-initiated research funding or received compensation as advisors or lecturers from AbbVie Corporation and MedImmune. M.S. and D.K. have no conflicts of interest to declare. AbbVie had no role in the study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript. No honorarium, grant, or other form of payment was given to anyone to produce the manuscript.

: The study was approved by The Research Ethics Board of each of the 32 centers involved in the recruitment of subjects.